Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 807-814

  Duffull, Stephen B ^a   Wright, Daniel F B ^a   Winter, Helen R ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

Pharmacodynamics; Pharmacokinetics; Pharmacometrics; Population analyses; Statistical models

Indexed keywords

GENTAMICIN;

ANALYSIS; ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RESPONSE; EXTRACT; FOLLOW UP; HUMAN; INDIVIDUALIZATION; INFORMATION; MEDICINE; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PUBLICATION; READING; SINGLE DRUG DOSE; STATISTICS; STUDY DESIGN;

HUMANS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; POPULATION; RESEARCH;

EID: 79955844576     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03891.x     Document Type: Article

References (37)

1. Wright DFB, Winter HR, Duffull SB. Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol 2011; 71: 815-23.
2. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972; 5: 411-59.
3. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5: 445-79.
4. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9: 635-51.
5. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11: 303-19.
6. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8: 553-71.
7. Pillai G, Mentre F, Steimer J-L. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161-83.
8. Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255-64.
9. Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46: 321-33.
10. Bonate PL. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J 2005; 7: E363-73.
11. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907-15.
12. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702-6.
13. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 2004; 38: 2136-44.
14. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB. The time course of drug effects. Pharm Stat 2009; 8: 176-85.
15. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006; 33: 227-79.
16. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42: 283-90.
17. Wade JR, Edholm M, Salmonson T. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS Journal 2005; 7: 45.
18. Grasela TH, Dement CW, Kolterman OG, Fineman MS, Grasela DM, Honig P, Antal EJ, Bjornsson TD, Loh E. Pharmacometrics and the transition to model-based development. Clin Pharmacol Ther 2007; 82: 137-42.
19. Senn S. Statisticians and pharmacokineticists: what they can still learn from each other. Clin Pharmacol Ther 2010; 88: 328-34.
20. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R. Model-based drug development. Clin Pharmacol Ther 2007; 82: 21-32.
21. Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn 2005; 32: 521-45.
22. Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles BG, Duffull SB. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol 2007; 63: 438-50.
23. Roos JF, Kirkpatrick CM, Tett SE, McLachlan AJ, Duffull SB. Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. Br J Clin Pharmacol 2008; 66: 455-66.
24. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56: 96-103.
25. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-35.
26. Bouillon T, Meineke I, Port R, Hildebrandt R, Gunther K, Gundert-Remy U. Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Eur J Clin Pharmacol 1996; 51: 153-60.
27. Jordan P, Goggin T, Pillai G, Steimer J-L, Fotteler B, Gieschke R. Modeling and simulation of clinical trials. In: Simulation for Designing Clinical Trials: Informa Healthcare. 2002.
28. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88: 166-82.
29. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther 2010; 87: 727-34.
30. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37: 3-24.
31. Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR. Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol 2006; 62: 165-76.
32. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2004; 59: 281-90.
33. Hulot J-S, Vantelon C, Urien S, Bouzamondo A, Mahe I, Ankri A, Montalescot G, Lechat P. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004; 26: 305-10.
34. Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P, Group PS. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol 2007; 64: 428-38.
35. Kane-Gill SL, Feng Y, Bobek MB, Bies RR, Pruchnicki MC, Dasta JF. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. J Clin Pharm Ther 2005; 30: 207-13.
36. O'Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost 2007; 5: 1985-7.
37. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn 2004; 31: 109-34.